GGrantIndex
← Leaderboards

International Agency For Res On Cancer

Lyon

Compare ↔
$68,288,208
Total funding
45
Grants

Funding over time

peak $4.8M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$67,760,708 · 44
CDC$527,500 · 1

By mechanism

U01$33,684,328 · 8
R01$20,196,568 · 11
UH3$6,001,239 · 2
R03$2,084,822 · 16
UH2$1,899,144 · 2
R37$1,730,892 · 1

Investigators at International Agency For Res On Cancer

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

1Mary K. Schubauer-Berigan$4,871,9491 gr2Partha Basu$1,730,8921 gr3Isabel Dos Santos Silva$964,5291 gr4Tarik Gheit$288,7121 gr5Shama Virani$221,8171 gr

All-Time

Most funded here, all years

1Sean Vahram Tavtigian$12,451,9526 gr2Paul Joseph Brennan$5,186,1056 gr3Mary K. Schubauer-Berigan$4,871,9491 gr4David E. Goldgar$2,780,3413 gr5Partha Basu$1,730,8921 gr6Elisabeth Cardis$1,498,9331 gr7Valerie McCormack$1,325,5443 gr8Isabel Dos Santos Silva$964,5291 gr

Largest grants

One-carbon metabolism biomarkers and lung cancer risk$1,751,854
U01 · FY2011 · CA
One-carbon metabolism biomarkers and lung cancer risk$1,665,211
U01 · FY2012 · CA
Pooled genome-wide analysis of kidney cancer risk$1,235,811
U01 · FY2011 · CA
Pooled genome-wide analysis of kidney cancer risk$1,195,864
U01 · FY2012 · CA
Breast &prostate cancer &hormone-related gene variants$1,056,889
U01 · FY2003 · CA
IARC Monographs on the Identification of Carcinogenic Hazards to Humans$990,253
R01 · FY2023 · CA
IARC Monographs on the Identification of Carcinogenic Hazards to Humans$990,253
R01 · FY2025 · CA
IARC Monographs on the Identification of Carcinogenic Hazards to Humans$980,253
R01 · FY2021 · CA
IARC Monographs on the Identification of Carcinogenic Hazards to Humans$970,449
R01 · FY2022 · CA
Breast &prostate cancer &hormone-related gene variants$960,687
U01 · FY2004 · CA
IARC Monographs on the Identification of Carcinogenic Hazards to Humans$940,741
R01 · FY2024 · CA
Pooled genome-wide analysis of kidney cancer risk$932,434
U01 · FY2013 · CA
Evaluation of Carcinogenic Risks to Humans$925,343
U01 · FY2016 · CA
Evaluation of Carcinogenic Risks to Humans$924,535
U01 · FY2017 · CA
Evaluation of Carcinogenic Risks to Humans$921,807
U01 · FY2018 · CA
Evaluation of Carcinogenic Risks to Humans$900,230
U01 · FY2020 · CA
Evaluation of Carcinogenic Risks to Humans$893,966
U01 · FY2019 · CA
Development and clinical validation of a multi-type HPV E6/E7 oncoprotein test for cervical cancer screening and triage in low- and middle-income countries$874,156
UH3 · FY2019 · CA
Evaluation of Carcinogenic Risks to Humans$858,889
U01 · FY2010 · CA
Development and clinical validation of a multi-type HPV E6/E7 oncoprotein test for cervical cancer screening and triage in low- and middle-income countries$850,346
UH3 · FY2020 · CA